Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MedCanDem: Medical Cannabinoids for Behavioral Symptoms in Severe Dementia
NCT05432206Phase 3Completed
- Sponsor
- FAHPA
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Dementia comparing Cannabis Sativa Oil first with Placebo first (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory at 8 weeks. Started Sep 2023; status: completed.
02
Drugs
full-spectrum cannabis oil
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT05432206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432206.